NEUROCRINE BIOSCIENCES, INC. (NBIX) Return on equity 2016–2025
NEUROCRINE BIOSCIENCES, INC. (NBIX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.7%FY2025 · since FY2016: -44.8% → 14.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.7% | +1.5 pp |
| FY2024 | 13.2% | +2.0 pp |
| FY2023 | 11.2% | +2.1 pp |
| FY2022 | 9.0% | +2.5 pp |
| FY2021 | 6.5% | -29.6 pp |
| FY2020 | 36.2% | +30.4 pp |
| FY2019 | 5.8% | +1.4 pp |
| FY2018 | 4.4% | +42.7 pp |
| FY2017 | -38.3% | +6.5 pp |
| FY2016 | -44.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice